Evidence map›Paper›PMID 39991240›Full record

ArticleHeliyon2025

Updating the "cost factor" in the William fine risk assessment method following economic power: A case study of selected production industries in Iran.

Bafrin Moloudpourfard, Morteza Tahamipour Zarandi, Mostafa Pouyakian

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bafrin MoloudpourfardDepartment of Occupational Health Engineering, School of Public Health and Allied Medical Sciences, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Morteza Tahamipour ZarandiDepartment of Economics, Faculty of Economics and Political Science, Shahid Beheshti University, Tehran, Iran.
Mostafa PouyakianDepartment of Occupational Health and Safety Engineering, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The William Fine approach is among the limited number of methods, introducing a metric referred to as the J index and discussing safety costs to evaluate control measures. Therefore, this study aimed to update the "cost factor" in the William Fine method in proportion to the economic power in selected production industries in Iran. Based on the International Standard Industrial Classification (ISIC), three selected production industries were the automotive, pharmaceutical, and food industries. The Delphi technique was used to achieve the values of safety costs in economic sectors. Due to high exchange rate fluctuations and the possibility of using the cost invoice table over time and the producer price index, the correction factor was calculated. Furthermore, the fuzzy logic method determined the cost factor of William Fine's method. The gap between the minimum and maximum costs is significantly broader in the automotive industry compared to the pharmaceutical and food industries. The cost factor correction for the automotive industry stands at 1.144, while it is 1.222 for pharmaceuticals and 1.141 for the food industry. These figures are expected to be generalized in the coming years. The present study revealed that due to the impossibility of accurate access to data related to cost performance and safety investment in industries, the Delphi method could be acceptable to achieve the range of safety costs in industries. Updating this table has enabled selected industries to achieve more accurate control costs or risk aversion estimates.

Indexed as

Control measuresCost factorRisk assessmentSafety costWilliam fine

Identifiers

PMID39991240
PMCPMC11847050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.